MetabolicHuman RCT
Retatrutide: what the trials show so far, and what is still a press release
Peer-reviewed trials show 24% weight loss at 48 weeks and large falls in liver fat; the headline 28% phase 3 figure is still company-reported.
Retatrutide
An investigational weekly GIP, GLP-1 and glucagon receptor agonist from Eli Lilly with published phase 2 and phase 3 trials; not yet approved anywhere.
- Also known as
- LY3437943, triple agonist, GGG tri-agonist
- Area
- Metabolic
- Status
- Investigational; not approved in the UK or US. Lilly plans a US filing in early 2027
Articles on Retatrutide
MetabolicHuman RCT
Retatrutide’s phase 2 trial: 24% weight loss at 48 weeks, in 338 people
The top dose took off 24.2% of body weight against 2.1% on placebo. It’s a striking number from a mid-sized, US-only trial with a generous way of counting.